TransCytos, LLC. develops devices and processes for delivering cell and gene therapies to patients, enabling their own cells to treat cancer, autoimmune, infectious, and rare diseases. Their non-viral Slipstream™ platform technology introduces molecules into patient cells to enhance immune capabilities or correct gene defects without the need for chemotherapy, radiation, or viruses. The Slipstream™ process streamlines therapy delivery, eliminates costly drug development processes, and overcomes limitations of virus-based cell modification technologies. TransCytos aims to bring therapy delivery to the patient's bedside, reduce treatment timeframes, and address historically neglected rare diseases, with a focus on developing broadly applicable therapy platforms for multi-trillion-dollar markets.